Scarica l'app Stockscreener
3.82
1.29%
-0.05
Precedente Chiudi:
$3.87
Aprire:
$3.88
Volume 24 ore:
1.72M
Relative Volume:
0.84
Capitalizzazione di mercato:
$631.22M
Reddito:
$361.51M
Utile/perdita netta:
$102.18M
Rapporto P/E:
6.3944
EPS:
0.5974
Flusso di cassa netto:
$112.21M
1 W Prestazione:
+4.95%
1M Prestazione:
-6.14%
6M Prestazione:
+6.11%
1 anno Prestazione:
+115.82%
Intervallo 1D:
$3.81
$3.95
Intervallo di 1 settimana:
$3.54
$3.965
Portata 52W:
$1.41
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Nome
Ironwood Pharmaceuticals Inc
Settore
Telefono
617-621-7722
Indirizzo
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
3.82 | 631.22M | 361.51M | 102.18M | 112.21M | 0.5974 |
TAK
Takeda Pharmaceutical Co Adr
|
18.73 | 59.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.10 | 47.93B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.32 | 40.99B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
74.81 | 30.91B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.16 | 23.55B | 3.17B | 1.29B | 1.01B | 27.09 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | Downgrade | Jefferies | Buy → Hold |
| 2025-04-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | Iniziato | Leerink Partners | Market Perform |
| 2024-08-08 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Iniziato | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Wells Fargo | Overweight |
| 2023-11-09 | Iniziato | Jefferies | Buy |
| 2023-09-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-02 | Iniziato | CapitalOne | Overweight |
| 2022-04-22 | Iniziato | Piper Sandler | Overweight |
| 2020-09-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Iniziato | Northland Capital | Outperform |
| 2019-07-10 | Ripresa | Credit Suisse | Neutral |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Iniziato | H.C. Wainwright | Sell |
| 2018-05-09 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Downgrade | Mizuho | Buy → Neutral |
| 2017-07-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Iniziato | Wells Fargo | Outperform |
| 2017-04-07 | Reiterato | Mizuho | Buy |
| 2017-02-22 | Reiterato | Barclays | Equal Weight |
| 2016-11-04 | Reiterato | Mizuho | Buy |
| 2016-10-24 | Reiterato | Wedbush | Neutral |
| 2016-10-10 | Reiterato | Mizuho | Buy |
| 2016-09-27 | Reiterato | WallachBeth | Hold |
Mostra tutto
Ironwood Pharmaceuticals Inc Borsa (IRWD) Ultime notizie
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? - Zacks Investment Research
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? - Zacks Investment Research
Form 144 IRONWOOD PHARMACEUTICALS INC For: 27 September By Investing.com - Investing.com Australia
Form 144 IRONWOOD PHARMACEUTICALS INC For: 27 September By Investing.com - Investing.com Nigeria
Form 144 IRONWOOD PHARMACEUTICALS INC For: 27 September By Investing.com - Investing.com India
83,306 shares to cover taxes: Ironwood Pharmaceuticals (IRWD) ex-officer proposes a sale - Stock Titan
Ironwood Pharmaceuticals Director Alexander J. Denner Awarded 3,694 Shares Under Compensation Policy - Kalkine Media
Ironwood: Medicare Is Not The Problem I Thought It Was - Seeking Alpha
Ironwood Pharmaceuticals at Wells Fargo conference: linzess rebound drives turnaround - Investing.com Canada
Ironwood Pharmaceuticals at Wells Fargo conference: linzess rebound drives turnaround - Investing.com UK
IRWD Stock Price, Quote & News - Syfe
IRWD stock gains as Wells Fargo conference spotlight shifts to cash flow - ad-hoc-news.de
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
Ironwood Pharmaceuticals (IRWD) Slips 2.6% as Shares Approach Key Support at $3.92Backspread Trade - vinanet.vn
Ironwood Pharmaceuticals (IRWD) Slips 2.59% to $4.13: Analyzing Key Support and Resistance LevelsETF Flow - dars.gov.et
Ironwood Pharmaceuticals Inc. Class A (IRWD) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Ironwood Pharmaceuticals: High Dependence On Its Next Trial (NASDAQ:IRWD) - Seeking Alpha
Ironwood (IRWD) Results Versus Estimates: EPS Does Not Reach the Reported Estimate for the Current Session; Market Move: The Market Price Moves 1.16% Higher in Latest TradingEarnings Yield Analysis - vinanet.vn
Ironwood Pharmaceuticals (IRWD) Edges Higher: Shares Advance 1.16% as Bulls Defend Key SupportRSI Oversold Picks - vinanet.vn
Ironwood Pharmaceuticals (IRWD) Edges Higher: Shares Advance 1.16% as Bulls Defend Key SupportValue ETF - dars.gov.et
Jeffrey Silber Net Worth (2026) - GuruFocus
Bank of America Corp DE Sells 2,838,753 Shares of Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals | ARS: Annual Report to Security Holders - Moomoo
Ironwood Pharmaceuticals (IRWD) Q2 2026 Earnings: EPS Misses Estimates, Stock Climbs 5.64%Dividend Growth Analysis - vinanet.vn
Armistice Capital (IRWD) discloses 13.9M-share Ironwood Pharmaceuticals stake - stocktitan.net
Dimensional Fund Advisors LP Raises Holdings in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap DownTime to Sell? - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Ironwood Pharmaceuticals, Inc. $IRWD Shares Sold by Amundi - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
State Street Corporation (NYSE: IRWD caretaker) holds 5.4% of Ironwood common stock - Stock Titan
Ironwood Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Pacer Advisors Inc. Makes New $3.98 Million Investment in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised - Eastern Progress
Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call High - GuruFocus
Ironwood Pharmaceuticals (IRWD) Is Up 14.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed? - Yahoo! Finance Canada
Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call Highlights: Strong LINZESS Growth ... - Yahoo Finance
IRWD Looks 15.8% Undervalued on GF Value™ as Debt Reduction Effo - GuruFocus
Ironwood Pharmaceuticals Q2 Earnings Call Highlights - Yahoo Finance
Ironwood Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:IRWD) 2026-08-06 - Seeking Alpha
Is Ironwood Pharmaceuticals (IRWD) Undervalued After Q2 Earnings - GuruFocus
IRWD: LINZESS sales surged and guidance was raised as apraglutide advanced in phase III trials - TradingView
Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates - Yahoo Finance
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Ironwood Raises 2026 Guidance After Q2 Revenue Hits $113 Million - Quiver Quantitative
BRIEF-Ironwood Pharmaceuticals Q2 Revenue USD 113.041 Million Vs. IBES Estimate USD 114.8 Million - TradingView
Press Release: Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results - Moomoo
Segall Bryant & Hamill LLC Buys New Position in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Lazard Asset Management LLC Sells 710,256 Shares of Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results - Business Wire
Ironwood Pharmaceuticals Inc Azioni (IRWD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ironwood Pharmaceuticals Inc Azioni (IRWD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| RONALD SILVER | Officer |
Jul 07 '26 |
Proposed Sale |
4.38 |
127,890 |
560,158 |
0 |
| Silver Ronald | PFO & PAO |
Jul 07 '26 |
Sale |
4.52 |
127,890 |
578,063 |
313,680 |
| McHugh Julie | Director |
Jun 16 '26 |
Sale |
3.73 |
21,571 |
80,460 |
250,749 |
| JULIE MCHUGH | Director |
Jun 16 '26 |
Proposed Sale |
3.69 |
21,571 |
79,597 |
0 |
| DENNER ALEXANDER J | Director |
Mar 17 '26 |
Sale |
3.05 |
6,730,800 |
20,530,448 |
9,188,635 |
| MCCOURT Thomas A | Chief Executive Officer |
Feb 24 '26 |
Sale |
3.66 |
103,526 |
378,905 |
1,489,002 |
| Silver Ronald | Principal Accounting Officer |
Feb 24 '26 |
Sale |
3.66 |
12,621 |
46,193 |
252,636 |
| Gaskins Tammi L | Chief Commercial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,239 |
41,135 |
213,738 |
| Martini Gregory S. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,457 |
41,933 |
160,601 |
| John Minardo | Chief Legal Officer |
Feb 24 '26 |
Sale |
3.66 |
19,053 |
69,734 |
363,886 |
0.42%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):